

ongoing trials - trial from www.clinicaltrials.gov

Antibiotic Treatment Of Staphylococcus Aureus In Stable People With CF - Phase 3 - Recruiting

Code: NCT04553419 **Year:** 2020 **Date:** July 27, 2020

Author: University of British Columbia|The Hospital for Sick Children

Study design (if review, criteria of inclusion for studies)

Interventional - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment

Participants

Cystic Fibrosis - 3 Years to 16 Years (Child)

Interventions

Drug: Cephalexin|Drug: Placebo

Outcome measures

The relative change in LCI2.5 between day 0 and day 14 (relative change = [LCI2.5 at day 14-LCI2.5 at day 0]/LCI2.5 at day 0).|Time to next pulmonary exacerbation|Relative change in percent predicted FEV1 between day 0 and day 14|Absolute change in FEV1 (mL) between day 0 and day 14|Relative change in LCI5 between day 0 and day 14.|Absolute change in LCI2.5 and LCI5 between day 0 and day 14|Absolute change in the CFQ-R(R) between day 0 and day 14.|MSSA airway culture positivity at day 14|Time until next growth of MSSA on clinical microbiology samples|Number of new CF respiratory pathogens (P. aeruginosa etc) from clinical respiratory samples

<https://ClinicalTrials.gov/show/NCT04553419>

Keywords

Anti-Bacterial Agents; Bacterial Infections; Cephalexin; Child; Infant; Infection; pharmacological_intervention; Pneumonia; Respiratory Tract Diseases; Respiratory Tract Infections; Staphylococcus aureus; Continuous; Cephalosporins;